Astrazeneca plc — RNS

Regulatory news across AZN

Date	Time	Date	TitleTitle (filtered)	Source
21/06/22	07:00:06	21 Jun 2022	Eplontersen Ph III trial met co-primary endpoints	Eplontersen Ph III trial met co-primary endpoints	RNS
06/06/22	07:00:09	6 Jun 2022	Enhertu efficacy results in HER2-low breast cancer	Enhertu efficacy results in HER2-low breast cancer	RNS
01/06/22	15:00:00	1 Jun 2022	Block listing Interim Review	Block listing Interim Review	RNS
01/06/22	15:00:00	1 Jun 2022	Total Voting Rights	Total Voting Rights	RNS
20/05/22	16:00:04	20 May 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
09/05/22	13:00:01	9 May 2022	Appointment of joint corporate brokers	Appointment of joint corporate brokers	RNS
06/05/22	16:00:01	6 May 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
05/05/22	07:10:02	5 May 2022	Enhertu approved in US for 2L HER2+ breast cancer	Enhertu approved in US for 2L HER2+ breast cancer	RNS
05/05/22	07:05:01	5 May 2022	Farxiga HFpEF Phase III trial met primary endpoint	Farxiga HFpEF Phase III trial met primary endpoint	RNS
05/05/22	07:00:04	5 May 2022	Ultomiris NMOSD Ph. III trial met primary endpoint	Ultomiris NMOSD Ph. III trial met primary endpoint	RNS
04/05/22	07:00:04	4 May 2022	Imfinzi combo granted Priority Review for BTC	Imfinzi combo granted Priority Review for BTC	RNS
03/05/22	15:00:02	3 May 2022	Total Voting Rights	Total Voting Rights	RNS
29/04/22	17:30:04	29 Apr 2022	Result of AGM	Result of AGM	RNS
29/04/22	07:05:01	29 Apr 2022	AstraZeneca plans new R&D centre in Massachusetts	AstraZeneca plans new R&D centre in Massachusetts	RNS
29/04/22	07:00:03	29 Apr 2022	First quarter 2022 results	First quarter 2022 results	RNS
28/04/22	07:00:12	28 Apr 2022	Ultomiris approved in the US for adults with gMG	Ultomiris approved in the US for adults with gMG	RNS
27/04/22	07:00:11	27 Apr 2022	Enhertu granted BTD for HER2-low breast cancer	Enhertu granted BTD for HER2-low breast cancer	RNS
25/04/22	07:00:08	25 Apr 2022	Tremelimumab US Priority Review for Imfinzi combo	Tremelimumab US Priority Review for Imfinzi combo	RNS
19/04/22	07:00:11	19 Apr 2022	Enhertu granted Priority Review for HER2m NSCLC	Enhertu granted Priority Review for HER2m NSCLC	RNS
01/04/22	15:00:05	1 Apr 2022	Total Voting Rights	Total Voting Rights	RNS
29/03/22	07:00:09	29 Mar 2022	Ondexxya approved in Japan for FXai reversal	Ondexxya approved in Japan for FXai reversal	RNS
28/03/22	07:00:09	28 Mar 2022	Evusheld approved in the EU for COVID-19	Evusheld approved in the EU for COVID-19	RNS
25/03/22	15:30:06	25 Mar 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
24/03/22	18:00:06	24 Mar 2022	Evusheld Positive EU CHMP Opinion	Evusheld Positive EU CHMP Opinion	RNS
24/03/22	07:00:10	24 Mar 2022	Update on CALLA Phase III trial for Imfinzi	Update on CALLA Phase III trial for Imfinzi	RNS
23/03/22	11:00:02	23 Mar 2022	Notice of AGM	Notice of AGM	RNS
17/03/22	07:00:05	17 Mar 2022	Settlement of patent litigation for Ultomiris	Settlement of patent litigation for Ultomiris	RNS
14/03/22	07:05:07	14 Mar 2022	Lynparza approved in US for early breast cancer	Lynparza approved in US for early breast cancer	RNS
14/03/22	07:00:11	14 Mar 2022	Update on US review of Fasenra in nasal polyps	Update on US review of Fasenra in nasal polyps	RNS
09/03/22	15:30:01	9 Mar 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
07/03/22	15:30:01	7 Mar 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
01/03/22	15:30:01	1 Mar 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
01/03/22	15:00:01	1 Mar 2022	Total Voting Rights	Total Voting Rights	RNS
01/03/22	07:00:06	1 Mar 2022	AstraZeneca and Neurimmune close deal for NI006	AstraZeneca and Neurimmune close deal for NI006	RNS
23/02/22	07:00:02	23 Feb 2022	Filing of Form 20-F with SEC	Filing of Form 20-F with SEC	RNS
22/02/22	11:00:00	22 Feb 2022	Chair succession planning update and Annual Report	Chair succession planning update and Annual Report	RNS
21/02/22	07:00:09	21 Feb 2022	Enhertu improves PFS and OS in HER2-low BC	Enhertu improves PFS and OS in HER2-low BC	RNS
16/02/22	07:00:08	16 Feb 2022	Saphnelo approved in EU for SLE	Saphnelo approved in EU for SLE	RNS
15/02/22	07:00:06	15 Feb 2022	Lynparza combo delays progression risk in prostate	Lynparza combo delays progression risk in prostate	RNS
11/02/22	15:30:02	11 Feb 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
10/02/22	07:00:03	10 Feb 2022	AZN: Full year and Q4 2021 results	AZN: Full year and Q4 2021 results	RNS
01/02/22	15:00:05	1 Feb 2022	Total Voting Rights	Total Voting Rights	RNS
19/01/22	07:05:08	19 Jan 2022	Imfinzi improves survival in biliary tract cancer	Imfinzi improves survival in biliary tract cancer	RNS
19/01/22	07:00:07	19 Jan 2022	Imfinzi combo shows unprecedented survival in HCC	Imfinzi combo shows unprecedented survival in HCC	RNS
17/01/22	07:00:07	17 Jan 2022	Enhertu granted Priority Review for breast cancer	Enhertu granted Priority Review for breast cancer	RNS
07/01/22	07:00:07	7 Jan 2022	AstraZeneca and Neurimmune sign deal for NI006	AstraZeneca and Neurimmune sign deal for NI006	RNS
05/01/22	07:00:08	5 Jan 2022	Transfer of rights to Eklira, Duaklir completed	Transfer of rights to Eklira, Duaklir completed	RNS
04/01/22	15:00:07	4 Jan 2022	Total Voting Rights	Total Voting Rights	RNS
29/12/21	07:00:11	29 Dec 2021	AstraZeneca and Ionis close eplontersen deal	AstraZeneca and Ionis close eplontersen deal	RNS
21/12/21	07:00:05	21 Dec 2021	Ultomiris accepted for FDA Priority Review for gMG	Ultomiris accepted for FDA Priority Review for gMG	RNS

Showing 401–450 of 485 announcements